Printer-friendly versionPrinter-friendly version

Can the United Kingdom control viral hepatitis?

Edinburgh, United Kingdom, November 17-18, 2005

Thursday, November 17, 2005

Session 1 Opening and objectives

Chair: Claire Cameron and Mark Kane

09.00 - 09.20

  • Welcome
  • Introduction of the participants
  • Objectives of the meeting:
    • How England, Wales, Scotland, and Northern Ireland fit together – politics, healthcare, decision making, research, funding;
    • Update of the epidemiological situation on viral hepatitis (A, B, C) in the UK;
    • Viral hepatitis: virology, clinical aspects, control, public health aspects, economic aspects;
    • Hepatitis B vaccination in the UK: selective or selective plus universal?
    • Hepatitis C: testing, management, modelling, and national strategy.
    • Lessons learnt from the UK experience.
  • Pre-meeting document 385 Kb (.pdf)

Session 2 Scene setting

Chair: Claire Cameron and Mark Kane

09.20 - 10.15
How England, Wales, Scotland, and Northern Ireland fit together – politics, healthcare, decision making, research, funding 129 Kb (.pdf)
Howard Thomas, London, UK

10.15 - 10.30
Coffee break

Session 3 Hepatitis B: selective vaccination or selective plus universal vaccination

Chair: David Goldberg and André Meheus

10.30 – 11.00
Epidemiology of hepatitis B in the UK 680 Kb (.pdf)
Mary Ramsay, London, UK

11.00 - 11.30
Virology of hepatitis B 1150 Kb (.pdf)
William Carman, Glasgow, UK

11.30 – 12.00
Clinical aspects 324 Kb (.pdf)
Geoffrey Dusheiko, London, UK

12.00 - 13.30
Lunch

13.30 – 14.00
Hepatitis B: public health aspects – Glasgow 208 Kb (.pdf)
Syed Ahmed, Glasgow, UK

14.00 - 14.30
Hepatitis B: public health aspects – London 1074 Kb (.pdf)
Helen Maguire, London, UK

14.30 – 15.00
Hepatitis B: economic aspects 211 Kb (.pdf)
John Edmunds, London, UK

15.00 - 15.15
Coffee break

Session 4 Hepatitis C

Chair: Howard Thomas and Daniel Lavanchy

15.15 - 15.45
Epidemiology of hepatitis C in the UK 556 Kb (.pdf)
Kirsty Roy, Glasgow, UK

15.45 - 16.15
The cost effectiveness of case-finding strategies for HCV infection in former injecting drug users 148 Kb (.pdf)
Ken Stein, Exeter, UK

16.15 - 16.45
Management of diagnosed cases of hepatitis C virus infection 534 Kb (.pdf)
Mark Thursz, London, UK

16.45 - 17.15
National hepatitis C strategy / Action plans / SIGN guidelines 492 Kb (.pdf)
John Dillon, UK

Friday, November 18, 2005

Session 4 Hepatitis C (Continued)

Chair: Mary Ramsay and Daniel Shouval

09.00 - 09.30
Hepatitis C virus infection: monitoring of end-stage liver disease and modelling the current and future burden of disease 564 Kb (.pdf)
Sharon Hutchinson, Glasgow, UK

09.30 – 10.00
Modelling transmission of HCV among intravenous drug users and in prisons 174 Kb (.pdf)
Matthew Hickman, London, UK

10.00 - 10.30
Hepatitis C: economic issues 85 Kb (.pdf)
Richard Grieve, London, UK

10.30 - 11.00
Coffee break

Session 5 Hepatitis A

Chair: Mary Ramsay and Daniel Shouval

11.00 - 11.55
Epidemiology and control of hepatitis A in the UK 329 Kb (.pdf)
Natasha Crowcroft, London, UK

11.55 - 13.45
Lunch

Session 6 Conclusions of the meeting

Chair: William Carman and Steven Wiersma

13.45 - 14.45  
VHPB preliminary meeting conclusions 50 Kb (.pdf)
Guido François

14.45
Close of the meeting

Tags: